Publications by authors named "F Coury"
Objectives: To investigate the risk and predictors of severity and mortality of COVID-19 infection in patients with Connective Tissue Diseases (CTDs).
Methods: Using the French nationwide claims and hospitalization database, we assembled a nation-wide exhaustive cohort of adult CTD patients with rheumatoid arthritis, systemic lupus, Sjögren's disease, inflammatory myopathies, systemic sclerosis. We analyzed the rates of hospitalization, severe inpatient stays (intensive care unit [ICU] admissions or in-hospital mortality), and in-hospital mortality with COVID-19 from January 1st to December 31st, 2020.
Article Synopsis
- The study focuses on SB5, an adalimumab biosimilar approved in Europe in 2017, and aims to gather real-world data on its usage and effectiveness in patients with various immune-mediated inflammatory diseases (IMIDs).
- Researchers analyzed clinical and healthcare claims data from the French national healthcare database to assess patient persistence on SB5 after 12 months.
- Among 911 patients treated with SB5, notable remission rates were observed at the 12-month mark, particularly in naïve patients, across various conditions such as rheumatoid arthritis and Crohn's disease, with all showing significant improvement from baseline.
Chemical Short-Range Order (CSRO) has attracted recent attention from many researchers, creating intense debates about its impact on material properties. The challenges lie in confirming and quantifying CSRO, as its detection proves exceptionally demanding, contributing to conflicting data in the literature regarding its true effects on mechanical properties. Our work uses high-precision calorimetric data to unambiguously prove the existence and, coupled with atomistic simulations, quantify the type of CSRO.
View Article and Find Full Text PDFObjectives: Tropheryma whipplei infection can manifest as inflammatory joint symptoms, which can lead to misdiagnosis of inflammatory rheumatic disease and the use of disease-modifying antirheumatic drugs. We investigated the impact of diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease.
Methods: We initiated a registry including patients with disease-modifying antirheumatic drugs-treated inflammatory rheumatic disease who were subsequently diagnosed with Tropheryma whipplei infection.
Article Synopsis
- The study aims to assess the risk of global infections in patients with psoriatic arthritis (PsA) and axial spondyloarthritis who are treated with targeted therapies.
- They systematically reviewed data from 60 randomized controlled trials with over 20,000 patients to analyze the rates of infections linked to various treatments.
- Findings revealed a moderate increase in overall infection risk, particularly in patients with axial spondyloarthritis, mainly driven by the use of TNF and IL-17 inhibitors, but there was no notable increase in serious infections.